ASCO® 2023 Insights: "Expanding the Benefit - Dabrafenib/Trametinib as Tissue-Agnostic Therapy for BRAFV600E+ Adult & Pediatric Solid Tumors"

Login

Password

Forgot your password?

Join VuMedi

Select specialty

First name

Last name

Choose Password

About Us
Careers
Partner with us
F.A.Q
Contact us
Terms & conditions
Privacy policy

Playback speed

10 seconds

ASCO® 2023 Insights: "Expanding the Benefit - Dabrafenib/Trametinib as Tissue-Agnostic Therapy for BRAFV600E+ Adult & Pediatric Solid Tumors"

By Insights from 2023 ASCO® Annual Meeting FEATURING Vivek Subbiah

1,145 views

July 6, 2023

Vivek Subbiah, MD, now Chief of Early-Phase Drug Development for Sarah Cannon Research Institute (SCRI), ...
read more ↘ discusses the research conducted at The University of Texas MD Anderson Cancer Center, Houston, TX.
↖ read less

0 Comments

Explore the mechanism of Action of a TKI in HCC

Feat. W. Keiser

Child-Pugh Classification and its Role in Treatment Decisions in Pat…

Feat. P. Gholam

The Radiologist's Approach to Assessing Cancer Risk of Thyroid …

Feat. J. Langer